摘要:
The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.
摘要:
The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.
摘要:
The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.
摘要:
Methods for isothermal titration calorimetry analysis of the binding affinity of protease inhibitors to plasma proteins. A method that can quantitatively calculate free drug concentrations of protease inhibitors in human plasma, as well as a method to calculate therapeutic amounts and dosage regimens. Furthermore, the present invention provides a method that can calculate the effect of plasma proteins on the antiviral activity (EC50 values) of protease inhibitors from their binding affinities to plasma proteins. The present invention provides as well a method that can evaluate the in vivo anti-HIV efficacy of PIs in human plasma.
摘要:
Methods of identifying a fusion inhibitor and inhibitors of gp41-mediated membrane fusion are disclosed. The methods comprise, for example, providing a first helical polypeptide comprising a sequence of IQN17 (SEQ ID NO: 1); providing a second helical polypeptide of 34 or less than 34 amino acids comprising the amino acid sequence W-X1-X2-W-X3-X4-X5-I, wherein X1, X2, X3, X4, and X5 are each independently chosen from any amino acid except proline; measuring, by capillary zone electrophoresis, the degree of complex formation between these peptides; and comparing the measured degree of complex formation to the degree in the presence of a test composition.
摘要翻译:公开了鉴定融合抑制剂和gp41介导的膜融合抑制剂的方法。 所述方法包括例如提供包含IQN17(SEQ ID NO:1)序列的第一螺旋多肽; 提供包含氨基酸序列W-X1-X2-W-X3-X4-X5-I的34个或小于34个氨基酸的第二螺旋多肽,其中X1,X2,X3,X4和X5各自独立地选自 除脯氨酸以外的任何氨基酸; 通过毛细管区带电泳测量这些肽之间的复合物形成程度; 并将测量的复合物形成程度与存在测试组合物的程度进行比较。
摘要:
The present invention provides methods, systems and apparatus for encrypting and for decrypting a data stream, for securely sending a data stream and for securely receiving a data stream, and for secure transmission of a data stream. The data stream, after at least a part of it being encrypted, is transmitted from a sender to a receiver via a channel. An exemplary method for encrypting comprises: adjusting encryption attributes during transmission; encrypting the data stream according to the adjusted encryption attributes; and transmitting the encrypted data stream and information of the encryption attributes to the receiver.
摘要:
The invention discloses a system and method for reordering the request queue of the hardware accelerator, wherein, the request queue stores therein a plurality of coprocessor request blocks (CRBs) to be input into the hardware accelerator. The system including: content addressable memory connected to the request queue for storing the state pointer of each CRB in the request queue at a same physical storage location in the request queue, receiving the state pointer of a new CRB in response to the new CRB asking to join in the request queue and outputting the physical storage location of a CRB in the request queue whose state pointer stored in the content addressable memory is the same as the state pointer of the new CRB; and CRB insertion module for receiving the physical storage location of a CRB in the request queue whose state pointer is the same as the state pointer of the new CRB and inputting the new CRB in the request queue and the CRB in the request queue whose state pointer is the same as the state pointer of the new CRB adjacently into the hardware accelerator in the order of entering the request queue. The system and method can improve the process efficiency of the hardware accelerator.
摘要:
This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
摘要:
Methods for isothermal titration calorimetry analysis of the binding affinity of protease inhibitors to plasma proteins. A method that can quantitatively calculate free drug concentrations of protease inhibitors in human plasma, as well as a method to calculate therapeutic amounts and dosage regimens. Furthermore, the present invention provides a method that can calculate the effect of plasma proteins on the antiviral activity (EC50 values) of protease inhibitors from their binding affinities to plasma proteins. The present invention provides as well a method that can evaluate the in vivo anti-HIV efficacy of PIs in human plasma.
摘要:
The claimed invention is directed toward modified HIV-1 gp41 C-terminal heptad repeat fusion inhibitors. In particular, peptide derivatives of C-34 were prepared (e.g., FB006M) and modified with 3-maleimidoproionic acid (MPA), which allows rapid and irreversible conjugation to serum albumin at a 1:1 molar ratio. These polypeptides have an extended half-life in vivo and display potent antiviral activity against HIV-1.